SATB2 has been shown to suppress tumor progression in colorectal cancer, non‐small cell lung cancer and gastric cancer, and high SATB2 expression is associated with a favorable prognosis (Mansour et al, 2015; Wu et al, 2016; Ma et al, 2018). Here, SATB2 is linked to colorectal cancer.